Clinical Trial: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Transnational Randomized Study Comparing Carbon Ions Therapy Versus Conventional Radiotherapy - Including Protontherapy - for the Treatment of Radioresistant Tumors

Brief Summary: This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected radioresistant tumors. Eligible tumors are axial chordoma (except of base of skull), adenoid cystic carcinoma of head and neck (except of trachea) and sarcomas of any site (except chondrosarcoma of the skull base), non previously irradiated and without pre-planned surgery or chemotherapy after the clinical trial procedure. Randomization is balanced 1 for 1. Patients of the experimental arm are treated in carbon ions centers in Europe and patients of the standard arm are treated in France in their closest participating radiotherapy center. An accrual of 250 patients is needed and an absolute difference of 20% of relapse free survival at five years is awaited. The main endpoint is the progression free survival at five years. The trial is supported by the French program of clinical research and the national health insurance. Two associated studies are carried out: a radiobiological one looking for radioresistance markers in the sarcomas biopsies, and the second one is about medico economics.

Detailed Summary:
Sponsor: Hospices Civils de Lyon

Current Primary Outcome: Progression free survival (PFS) [ Time Frame: up to 5 years or loss of follow-up ]

Starting point for PFS measurement is the randomization date


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Grades of the CTCAE-V4.02 classification [ Time Frame: up to 5 years or loss of follow-up ]
    Tolerance
  • EQ-5D questionnaire [ Time Frame: up to 5 years or loss of follow-up ]
    Quality of life
  • Local progression free survival [ Time Frame: up to 5 years or loss of follow-up ]
    takes account of the local progression of the tumor in the planning target volume (PTV)
  • Metastases free survival [ Time Frame: up to 5 years or loss of follow-up ]
    takes account of any site of relapse outside of the PTV
  • Overall survival [ Time Frame: up to 5 years or loss of follow-up ]
    delay of death of any cause accounted starting from randomization


Original Secondary Outcome: Same as current

Information By: Hospices Civils de Lyon

Dates:
Date Received: July 18, 2016
Date Started: November 2016
Date Completion: May 2024
Last Updated: July 18, 2016
Last Verified: July 2016